- Chronic Myeloproliferative Disorders- Introduction2005 | First Faculty of Medicine
- Chronic Myeloproliferative Disorders- Introduction2005 | Faculty of Physical Education and Sport
- Anagrelide for Thrombocystosis in Myeloproliferative Disorders2004 | First Faculty of Medicine
- Anagrelide for Thrombocystosis in Myeloproliferative Disorders2004 | Faculty of Physical Education and Sport
- Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of Register for the 1st quarter of 20102010 | Faculty of Medicine in Hradec Králové
- Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome2008 | Second Faculty of Medicine
- Analysis of risk factor : the rationale of the guildelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia2006 | First Faculty of Medicine
- Philadelphia chromosome-negative myeloproliferative disorders:biology and treatment2007 | First Faculty of Medicine
- Philadelphia chromosome-negative myeloproliferative disorders:biology and treatment2007 | Faculty of Physical Education and Sport
- The WHO 2008 classification of Ph-myeloproliferative disorders: statement of the Czech MPD Working Group2008 | Second Faculty of Medicine
- Essential thrombocytemia in Ph negative myeloproliferative disorders (MPO-T) guidelines2006 | Faculty of Medicine in Hradec Králové
- Some New Findings in the Pathogenesis of Myeloproliferative Disorders and New Insight into More Effective Treament2006 | First Faculty of Medicine
- Antithrombotic prevention and treatment in thrombocytemias in Ph1 negative myeloproliferative disordersPublication without faculty affiliation
- The WHO 2008 classification of Ph-myeloproliferative disorders: statement of the Czech MPD Working Group2008 | Faculty of Medicine in Hradec Králové
- Chromosome 21 gain is dispensable for transient myeloproliferative disorder driven by a novel GATA1 mutation2020 | Second Faculty of Medicine
- The effectiveness of anagrelide treatment in patients with Ph-negative myeloproliferative diseases: Influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 20122013 | Faculty of Medicine in Hradec Králové
- Diagnosis of essential thrombocytemia. Definition of essential thrombocytemia and thrombocytemia associated with other Ph-negative myeloproliferative disorder (MPO) +12008 | Faculty of Medicine in Hradec Králové
- Diagnosis of essential thrombocytemia. Definition of essential thrombocytemia and thrombocytemia associated with other Ph-negative myeloproliferative disorder (MPO)2008 | First Faculty of Medicine
- Analysis of risk factors: The rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia2006 | Second Faculty of Medicine
- Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide2016 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Second Faculty of Medicine
- Analysis of risk factor : the rationale of the guildelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia2006 | Faculty of Medicine in Hradec Králové
- Analysis of risk factors: The rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia2006 | First Faculty of Medicine
- Analysis of risk factors: The rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia2006 | Faculty of Physical Education and Sport
- Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia2008 | Second Faculty of Medicine
- Surgical interventions in patients with myeloproliferative disease - prophylaxis and treatment of haemostatic disorders2010 | Faculty of Medicine in Hradec Králové
- Haematological malignancies +12008 | Faculty of Medicine in Hradec Králové
- Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study2008 | First Faculty of Medicine
- Diagnosis, etiology and management of the Budd-Chiari Syndrome: a bloodcoagulation and hepatological study on the course of the disease treated with TIPS2016 | Faculty of Medicine in Hradec Králové